Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Importance of Literature on Medical Device Development and Post Market Surveillance

Posted on November 13th, 2015 by

Chemistry

Medical devices

Before the ideation and creation of a novel prototype device — or the establishment of a new purpose for an existing one — medical device manufacturers must be confident that the device will serve a real need in the market. They must also establish that the device has unique value and will be safe and effective. Continue reading “The Importance of Literature on Medical Device Development and Post Market Surveillance” »

Using Reaxys for Lead Optimization: A Case Study

Posted on November 13th, 2015 by

Pharma R&D

dr-tucci

Epigen Biosciences is a start-up pharmaceutical company that collaborates with academic groups to discover innovative drugs for a range of medical conditions, including renal diseases, cancer and CNS disorders. Co-founder Dr. Fabio Tucci met with Elsevier to discuss how Epigen researchers use Reaxys to support their application of advanced hit-to-lead and lead optimization methods. Continue reading “Using Reaxys for Lead Optimization: A Case Study” »

Best Practices for Post-Market Surveillance Processes

Posted on November 13th, 2015 by

Pharmacovigilance

Medical-safety-2

Donna Sees, an Information Consultant with PharmIntell Consulting, has been a librarian in the medical field for more than 10 years. In this article, she discusses post-market surveillance processes and best practices for medical device companies.

Learn how PharmIntell Consulting took advantage of QUOSA.

More Drugs, Fewer Patients: Limits of Precision Medicine

Posted on November 9th, 2015 by

Chemistry

scientificamerican0809-70-I1

A number of targeted medications that are highly effective for a subgroup of patients with a particular disease have emerged in the last decade. These are often needed alternatives to debilitating therapies with uncertain outcomes. The small number of patients that benefit from such therapies, however, may pose a serious challenge looking into the future. Continue reading “More Drugs, Fewer Patients: Limits of Precision Medicine” »

Reaxys: Then & Now

Posted on October 30th, 2015 by

Chemistry

Reaxys_R&D

Reaxys, an online chemistry research solution from Reed Elsevier Properties SA, improves R&D productivity by delivering experimental facts on chemical structures, properties, reactions and procedures. It’s been around since 2009, but what came before it directly shaped what Reaxys was, what it is today and what it will be in the future. Discover the history of Reaxys. Continue reading “Reaxys: Then & Now” »

Ensuring the Safety of New Antipsychotics

Posted on October 30th, 2015 by

Chemistry

drug-safety

Antipsychotics have complex pharmacological profiles and adverse events are common with long-term use. New or optimized drugs with better safety profiles are desirable. The best way to get information on a new compound that has potential as an antipsychotic is to use in silico profiling to compare it to existing drugs, as described in this new paper.

Read all about drug safety of new antipsychotics.

  1. 1
  2. 52
  3. 53
  4. 54
  5. 55


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.